Abstract: Human polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for therapeutic purposes. Antagonists against such polypeptides and their use as a therapeutic are also disclosed. Also disclosed are diagnostic methods for detecting disease which utilize the sequences and polypeptides.

Abstract: A method of creating a peripheral driver for a particular peripheral by learning the peripheral options and the commands for those options from the peripheral itself. The computer access a specified location in the memory of the peripheral which contains either a generic peripheral description file or a pointer to such a file. The file is a text-based file, which contains the peripheral options as name-value entries. The computer parses the file and learns of the available options and the appropriate commands to use those options. The computer is thus able to create a driver for the peripheral.

Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Abstract: The present invention relates to a novel KDI protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a human interferon polypeptide, called “KDI”. KDI polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of KDI activity. Also provided are therapeutic methods for treating immune system-related disorders.

Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Abstract: A method for fabricating non-volatile memory cells is provided. The method includes providing a substrate, forming a first dopant region in the substrate, forming a second dopant region in the first dopant region, growing a first isolation region over a first portion of the substrate, the first dopant region, and the second dopant region, growing a second isolation region over a second portion of the substrate, the first dopant region, and the second dopant region, defining a contact region in the second dopant region, the contact region extending between the first isolation region and the second isolation region, depositing a gate oxide layer to form a first gate dielectric atop the first isolation region and a portion of the contact region, and overlaying a gate conductive layer on top of the gate oxide layer to form a first gate conductor atop the first gate dielectric.

Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Abstract: Human polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for therapeutic purposes. Antagonists against such polypeptides and their use as a therapeutic are also disclosed. Also disclosed are diagnostic methods for detecting disease which utilize the sequences and polypeptides.

Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Abstract: A receiver having a variable bit slicer for detecting bits in a demodulated signal, comprises a demodulator (14) for deriving a demodulated bit rate signal, means (36) for storing a plurality of threshold values, each of the threshold values being selectively adjustable, means (28, 38) for selecting the threshold value for comparison with the current bit signal (Sn) in response to a sequence of N bits (where N is at least 2) (Bn-1, Bn-2) received prior to the current bit (Bn) and means (38, 40) for using the current bit to update the selected threshold value. Also disclosed is a method of dc offset correction.

Abstract: A latch assembly includes a chassis and a rotatable claw-type latch bolt moveably mounted on the chassis. The latch bolt has a closed position for retaining a striker and an open position for releasing the striker. The latch bolt is provided with a latch abutment remote from a center of rotation. The latch assembly further includes a pawl rotatable about a pawl axis and having an engaged position for holding the latch bolt in the closed position and a disengaged position that allows the latch bolt to move to the open position. The latch assembly includes an eccentric arrangement defining a first axis and the pawl axis remote from the first axis. The latch assembly also includes a reset lever rotatably fixed to the eccentric arrangement for mutual rotation with the eccentric arrangement about the first axis. The latch assembly includes a biasing lever configured to transmit a biasing force to the reset lever at a position remote from the first axis and to the latch bolt via the latch abutment.

Abstract: A latch arrangement includes a power control system which can be energized to prevent opening of a door latch by controlling the movement of a release mechanism within a latch. A sensor monitors an operative state of the release mechanism. In the event the sensor detects an unauthorized attempt to open a door, the power control system is energized, thereby preventing unauthorized opening of the latch. The sensor can monitor the direct movement of a door handle. Additionally, or alternatively, the sensor can monitor an internal component within the release mechanism to monitor movements indicative of movement of the door handle.

Abstract: A BiCMOS integrated circuit (IC) includes a floating gate-type non-volatile memory (NVM) device that uses the polycrystalline silicon gate of a CMOS FET and the P-base and N-emitter diffusions of a bipolar transistor to provide an isolated P-type body and N-type source/drain diffusions. The P-body diffusion of the NVM device is isolated from a P-substrate by an N-well, thus facilitating the use of reduced positive and negative voltage levels to produce the onset of Fowler-Nordheim tunneling without the need for a triple-well structure. The polysilicon gate structure is formed on a suitable gate oxide over the P-body. The source/drain diffusions, which like the N-emitter diffusions of the bipolar transistor have no LDD, produce a reduced field drop across the gate oxide to allow Fowler-Nordheim tunneling from the source side.

Abstract: An apparatus for conditioning mammalian blood for subsequent use in a medical procedure includes a cabinet having a secure environment and a door providing the only access to the environment. An input system transports a blood charge from a source to the cabinet and a flask is removably contained in the secure environment and coupled to the charge input system to receive the charge. Stressors are coupled to the cabinet and positioned for operation to create a conditioned charge in the flask. An output system is coupled to the flask and includes a receiver for the conditioned charge. The apparatus includes an automated control system operable upon closing the door to lock the door and to then condition the charge, and to then cause the charge to move from the flask to the receiver.

Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Abstract: A latch arrangement includes a lever movable in response to movement of a door lever. A controller is configured for selectively preventing movement of the lever. The controller includes a mono-stable blocking element in the form of a bi-metallic strip which can be operated such that a distal end acts to block movement of the lever. The controller also includes a bi-stable blocking element having a nib that can be moved to an extended position to block movement of the lever. Both blocking elements can be operated at the same time. When either of the blocking elements are arranged in the path of the release lever, unlatching of the door is prevented.

Abstract: A non-volatile memory cell and method of fabrication are provided. The non-volatile memory cell includes a substrate of a first conductivity type, a first dopant region of a second conductivity type in the substrate, a second dopant region of the first conductivity type in the first dopant region, a first isolation region overlaying a portion of the substrate, the first dopant region, and the second dopant region, a second isolation region overlaying another portion of the substrate, the first dopant region, and the second dopant region, a contact region of the first conductivity type in the second dopant region, the contact region extending between the first isolation region and the second isolation region and being more heavily doped than the second dopant region, a gate dielectric atop the first isolation region and a portion of the contact region, and a gate conductor atop the gate dielectric.

Abstract: An apparatus for conditioning mammalian blood for subsequent use in a medical procedure includes a cabinet having a secure environment and a door providing the only access to the environment. An input system transports a blood charge from a source to the cabinet and a flask is removably contained in the secure environment and coupled to the charge input system to receive the charge. Stressors are coupled to the cabinet and positioned for operation to create a conditioned charge in the flask. An output system is coupled to the flask and includes a receiver for the conditioned charge. The apparatus includes an automated control system operable upon closing the door to lock the door and to then condition the charge, and to then cause the charge to move from the flask to the receiver.

Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.